TSO3 Enters Into First Commercial Agreement for STERIZONE VP4 Sterilizer


TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, announces that the company has signed its first commercial agreement with Getinge Infection Control in support of the launch of the STERIZONE® VP4 Sterilization System. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.

"We are extremely pleased to have Getinge Infection Control representing our STERIZONE® technology" says R.M. Rumble, president and CEO. "Our recent efforts which resulted in bolstering our balance sheet means that TSO3 has the financial resources available to support Getinge's sales efforts and after, sales service support. Getinge has watched the progression of our technology through the U.S. regulatory process and with US clearance now in-hand, both organizations see the opportunity to launch this superior technology in North America and selected additional markets" concluded Mr Rumble.

"Getinge Infection Control is the world leader in sterile reprocessing of reusable medical devices" says Andrew Ray, president and CEO of Getinge Infection Control North America. "The TSO3 technology fills a gap in our portfolio and is a natural fit for our commercial team. Our entire organization is anxious to get started assisting our mutual customers understand how this technology improves their process and reduces the cost of sterilization while improving patient outcomes."

The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low-temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for cost effective error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75-pound load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.

Source: TSO3 Inc.

Related Videos
Infection Control Today Topic of the Month: Mental Health
Infection Control Today Topic of the Month: Mental Health
An eye instrument holding an intraocular lens for cataract surgery. How to clean and sterilize it appropriately?   (Adobe Stock 417326809By Mohammed)
UV-C Robots by OhmniLabs.  (Photo from OhmniLabs website.)
CDC  (Adobe Stock, unknown)
Laparoscopy(Adobe Stock 338216574 by Damian)
Sterile processing   (Adobe Stock, unknown)
Jill Holdsworth, CIC, FAPIC, NREMT, CRCST, manager of infection prevention at Emory University Hospital Midtown; and Cheron Rojo, BS, FCs, CHL, CIS, CER, CFER, CRCST, clinical education coordinator for sterile processing departments, Healthmark
The Joint Commission Seal
Related Content